Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
- Sponsored Content
- Manufacturing
Developing a Platform for Large-Scale Lentiviral Manufacture
BPI Contributor
April 19, 2022
20 Min View
Date: Apr 18, 2022
Duration: 20 Min
Sponsored by WuXi Advanced Therapies
This webcast features: Yiyu Dong, PhD, Associate Director of Viral Vector Process Technology Development (VVPTD), WuXi Advanced Therapies.
Due to their capability for long-term transgene expression, large packaging capacity and ability to transduce postmitotic and quiescent cells, lentiviral vectors have become increasingly popular gene delivery tools for cell and gene therapies in recent years. However, capacity for lentiviral vector manufacture is a major industry bottleneck.
WuXi Advanced Therapies has developed a lentiviral suspension manufacturing platform using OXGENE’s XLenti™ packaging plasmids. Benefits of the XLenti™ suspension platform include:
A high producing single clonal cell line.
Chemically defined culture media.
High producing plasmids, optimized for increased translation efficiency and maximized expression of each cassette.
Simplified and efficient seed train.
Excellent scalability.
Robust upstream and downstream processes.
High viral titer.
This webinar will cover:
Performance data for WuXi Advanced Therapies’ XLenti™ suspension platform.
Solutions for large-scale manufacture of lentiviral vectors.
How to access OXGENE’s optimized XLenti™ packaging plasmids at research, clinical or commercial GMP grades.
Just fill out the form below to watch the recorded webcast now.
About the Author(s)
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More